Amy Evans
Family · Dallas, GANPI 1063800548
Payments from drug & device makers
Across 203 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$718
- Lilly USA, LLC$405
- Takeda Pharmaceuticals U.S.A., Inc.$138
- Pfizer$115
- Inspire Medical Systems, Inc.$112
- plus $411 from 12 others
What the payments were for
- Food & beverage$3,011100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 82 | $1,114 |
| AbbVie | 56 | $718 |
| Lilly USA, LLC | 28 | $405 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $138 |
| Pfizer | 6 | $115 |
| Inspire Medical Systems, Inc. | 1 | $112 |
| Amgen(2 entities) | 4 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Boston Scientific | 1 | $52 |
| Exact Sciences | 3 | $46 |
| GSK | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $20 |
| IBSA Pharma Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,011 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 26 | $36,960 |
| XareltoRivaroxaban | 14 | $12,315 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,341 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $6,467 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,465 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,028 |
| Gabapentin | 33 | $761 |
| Levothyroxine Sodium | 63 | $624 |
| Losartan Potassium | 47 | $394 |
| Atorvastatin Calcium | 69 | $342 |
| Pantoprazole Sodium | 50 | $326 |
| Omeprazole | 39 | $294 |
| Pravastatin Sodium | 28 | $277 |
| Duloxetine Hcl | 14 | $270 |
| Fluticasone Propionate | 20 | $212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,114 | $36,96026 claims |
| GSKTrelegy Ellipta | $38 | $11,34116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.
Other family in Dallas
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.